[1] ZHANG L, CHEN Y, JIN Y, et al. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients[J]. Thromb Res, 2013, 132(1): 81. doi: 10.1016/j.thromres.2013.05.006
[2] CEDILLO-SALAZAR FR, MARTÍNEZ-JACOBO L, PÉREZ-PÁRAMO YX, et al. Association of CYP2C19*2 polymorphism with clopidogrel resistance among patients with high cardiovascular risk in Northeastern Mexico[J]. Arch Cardiol Meéx, 2019, 89(4): 324.
[3] MARCHINI JF, PINTO MR, NOVAES GC, et al. Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients[J]. Braz J Med Biol Res, 2017, 50(1): e5660. doi: 10.1590/1414-431x20165660
[4] SIMON T, VERSTUYFT C, MARY-KRAUSE M, et al. Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl J Med, 2009, 360(4): 363. doi: 10.1056/NEJMoa0808227
[5] COSTACH II, RUSU C, IVANOV I, et al. Clopidogrel resistance-risk factor in patients with acute coronary syndromes[J]. Rev Med Chir Soc Med Nat Iasi, 2012, 116(2): 383.
[6] MEGA JL, CLOSE SL, WIVIOTT SD, et al. Genetic variants in ABCB1 and CYP2C19and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis[J]. Lancet, 2010, 376(9749): 1312. doi: 10.1016/S0140-6736(10)61273-1
[7] BLIDEN KP, DICHIARA J, TANTRY US, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?[J]. J Am Coll Cardiol, 2007, 49(6): 657. doi: 10.1016/j.jacc.2006.10.050
[8] KUO CH, LIU CJ, YANG CC, et al. A rapid and accurate method to evaluate helicobacter pylori infection, clarithromycin resistance and CYP2C19 genotypes simultaneously from gastric juice[J]. Medicine, 2016, 95(21): 3458. doi: 10.1097/MD.0000000000003458
[9] JIA DM, CHEN ZB, ZHANG MJ, et al. CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China[J]. Stroke, 2013, 44(6): 1717. doi: 10.1161/STROKEAHA.113.000823
[10] 倪贵华, 赵卫东, 田向阳, 等. CYP2C19和ABCBl基因多态性对脑梗死患者的氯吡格雷反应性和血管性事件的影响[J]. 中华神经科杂志, 2016, 49(7): 526. doi: 10.3760/cma.j.issn.1006-7876.2016.07.004
[11] LAMOUREUX F, DUFLOT T, WOILLARD JB, et al. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections[J]. Int Jantimicrob Ag, 2016, 47(2): 124. doi: 10.1016/j.ijantimicag.2015.12.003
[12] ZHOU SF, LIU JP, CHOWBAY B, et al. Polymorphism of human cytochrome P450 enzymes and its clinical impact[J]. Drug Metab Rev, 2009, 41(2): 89. doi: 10.1080/03602530902843483
[13] HULOT JS, BURA A, VILLARD E, et al. Cytochrome P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects[J]. Blood, 2006, 108(7): 2244. doi: 10.1182/blood-2006-04-013052
[14] WALLENTIN L, JAMES S, STOREY RF, et al. Effect of CYP2C19 and ABCB1 singlenucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel foracute coronary syndromes: a genetic substudy of the PLATO trial[J]. Lancet, 2010, 376(9749): 1320. doi: 10.1016/S0140-6736(10)61274-3
[15] SIBBING D, KOCH W, GEBHARD D, et al. Cytochrome 2C19* 17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement[J]. Circulation, 2010, 121(4): 512. doi: 10.1161/CIRCULATIONAHA.109.885194
[16] KIM KA, SONG WK, KIM KR, et al. Assessment of CYP2C19 genetic polymorphisms in a korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles[J]. J Clin Pharm Ther, 2010, 35(6): 697. doi: 10.1111/j.1365-2710.2009.01069.x
[17] TSELEPIS AD, TSOUMANI ME, KALANTZI KI, et al. Influence of high-density lipoprotein and paraoxonase-1 on platelet reactivity in patients with acute coronary syndromes receiving clopidogrel therapy[J]. J Thromb Haemost, 2011, 9(12): 2371. doi: 10.1111/j.1538-7836.2011.04541.x
[18] MARTÍNEZ-QUINTANA E, RODRÍGUEZ-GONZÁLEZ F, MEDINA-GIL JM, et al. Paraoxonase 1(Q192R) gene polymorphism, coronary heart disease and the risk of a new acute coronary event[J]. Clin Investig Arterioscler, 2017, 29(1): 1.
[19] SU J, XU J, LI X, et al. ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease(CAD) patients: a Meta-analysis[J]. PLoS One, 2012, 7(10): e46366. doi: 10.1371/journal.pone.0046366
[20] 时义宝, 李磊, 程鹏, 等. 替格瑞洛对急性冠脉综合征经皮冠状动脉介入治疗围术期血小板聚集率的影响[J]. 安徽医药, 2017, 21(9): 1673. doi: 10.3969/j.issn.1009-6469.2017.09.033